"These results demonstrate that our updated COVID-19 vaccine generates a strong human immune response against the highly mutated BA.2.86 variant.
"Moderna will continue to rapidly assess global public health threats and is committed to leveraging our mRNA platform against COVID-19."
The company’s announcement comes as the Biden administration prepares to authorize the updated shots from Moderna, Pfizer and Novavax as soon as next week.
While the shots target XBB.1.5, which was responsible for about 3% of new infections in recent weeks, researchers are optimistic that it will hold up against other circulating variants.
“With governments accelerating the timing of COVID-19 vaccination campaigns due to the potential risk of BA.2.86, Moderna has shared this data with regulators and is ready to supply its updated COVID-19 vaccine pending regulatory approval,” the company wrote in a press release.
Persons:
“ pirola, Stephen Hoge, Ashish Jha, ” Pirola, Biden
Organizations:
Moderna, Wednesday, EG, COVID, White, Centers for Disease Control, Pfizer, Novavax
Locations:
U.S, Moderna